Pharmacologic blockade of the natriuretic peptide clearance receptor promotes weight loss and enhances insulin sensitivity in type 2 diabetes

Published:December 20, 2022DOI:


      While natriuretic peptides (NPs) are primarily known for their renal and cardiovascular actions, NPs stimulate lipolysis in adipocytes and induce a thermogenic program in white adipose tissue (WAT) that resembles brown fat. The biologic effects of NPs are negatively regulated by the NP clearance receptor (NPRC), which binds and degrades NPs. Knockout (KO) of NPRC protects against diet induced obesity and improves insulin sensitivity in obese mice. To determine if pharmacologic blockade of NPRC enhanced the beneficial metabolic actions of NPs in type 2 diabetes, we blocked NP clearance in a mouse model of type 2 diabetes using the specific NPRC ligand ANP(4-23). We found that treatment with ANP(4-23) caused a significant decrease in body weight by increasing energy expenditure and reducing fat mass without a change in lean body mass. The decrease in fat mass was associated with a significant improvement in insulin sensitivity and reduced serum insulin levels. These beneficial effects were accompanied by a decrease in infiltrating macrophages in adipose tissue, and reduced expression of inflammatory markers in both serum and WAT. These data suggest that inhibiting NP clearance may be an effective pharmacologic approach to promote weight loss and enhance insulin sensitivity in type 2 diabetes. Optimizing the therapeutic approach may lead to useful therapies for obesity and type 2 diabetes.


      ANCOVA (analysis of covariance), ANP (atrial NP), BAT (brown adipose tissue), BNP (brain NP), CKD (chronic kidney diseases), CLAMS (Comprehensive LAb Monitoring System), CNP (C-type natriuretic peptide), HbA1c (hemoglobin A1c), HSL (hormone sensitive lipase), ITT (insulin tolerance test), KO (knockout), MCP1 (monocyte chemotactic protein-1), MRI (magnetic resonance imaging), NPRC (NP clearance receptor), NPRs (NP receptors), NPs (natriuretic peptides), PBS (phosphate buffered saline), PDEs (phosphodiesterases), RER (respiratory exchange ratio), UCP1 (uncoupling protein 1), US (United States), VCO2 (carbon dioxide release), VO2 (oxygen consumption), WAT (white adipose tissue), 1-α (peroxisome proliferator-activated receptor gamma coactivator)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chan RS
        • Woo J.
        Prevention of overweight and obesity: how effective is the current public health approach.
        Int J Environ Res Public Health. 2010; 7: 765-783
        • Cheng D.
        Prevalence, predisposition and prevention of type II diabetes.
        Nutr Metab (Lond). 2005; 2: 29
        • American Diabetes A
        Economic costs of diabetes in the U.S. in 2017.
        Diabetes Care. 2018; 41: 917-928
        • Potter LR
        • Abbey-Hosch S
        • Dickey DM.
        Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
        Endocr Rev. 2006; 27: 47-72
        • Bordicchia M
        • Liu D
        • Amri EZ
        • et al.
        Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes.
        J Clin Invest. 2012; 122: 1022-1036
        • Schlueter N
        • de Sterke A
        • Willmes DM
        • et al.
        Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome.
        Pharmacol Ther. 2014; 144: 12-27
        • Moro C
        • Lafontan M.
        Natriuretic peptides and cGMP signaling control of energy homeostasis.
        Am J Physiol Heart Circ Physiol. 2013; 304: H358-H368
        • Bae CR
        • Hino J
        • Hosoda H
        • et al.
        Adipocyte-specific expression of C-type natriuretic peptide suppresses lipid metabolism and adipocyte hypertrophy in adipose tissues in mice fed high-fat diet.
        Sci Rep. 2018; 8: 2093
        • Bae CR
        • Hino J
        • Hosoda H
        • et al.
        Overexpression of C-type natriuretic peptide in endothelial cells protects against insulin resistance and inflammation during diet-induced obesity.
        Sci Rep. 2017; 7: 9807
        • Miyashita K
        • Itoh H
        • Tsujimoto H
        • et al.
        Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity.
        Diabetes. 2009; 58: 2880-2892
        • Khan AM
        • Cheng S
        • Magnusson M
        • et al.
        Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies.
        J Clin Endocrinol Metab. 2011; 96: 3242-3249
        • Neeland IJ
        • Winders BR
        • Ayers CR
        • et al.
        Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile.
        J Am Coll Cardiol. 2013; 62: 752-760
        • Potter LR.
        Natriuretic peptide metabolism, clearance and degradation.
        FEBS J. 2011; 278: 1808-1817
        • Wu W
        • Shi F
        • Liu D
        • et al.
        Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance.
        Sci Signal. 2017; 10: 1-11
        • Francis SH
        • Busch JL
        • Corbin JD
        • et al.
        cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.
        Pharmacol Rev. 2010; 62: 525-563
        • Charles CJ
        • Espiner EA
        • Nicholls MG
        • et al.
        Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep.
        Am J Physiol. 1996; 271: R373-R380
        • Hashimoto Y
        • Nakao K
        • Hama N
        • et al.
        Clearance mechanisms of atrial and brain natriuretic peptides in rats.
        Pharm Res. 1994; 11: 60-64
        • Kukkonen P
        • Vuolteenaho O
        • Ruskoaho H.
        Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand.
        Endocrinology. 1992; 130: 755-765
        • Okolicany J
        • McEnroe GA
        • Koh GY
        • et al.
        Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor.
        Am J Physiol. 1992; 263: F546-F553
        • Moro C
        • Klimcakova E
        • Lafontan M
        • et al.
        Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis.
        Br J Pharmacol. 2007; 152: 1102-1110
        • Ceddia RP
        • Liu D
        • Shi F
        • et al.
        Increased energy expenditure and protection from diet-induced obesity in mice lacking the cGMP-specific phosphodiesterase PDE9.
        Diabetes. 2021; 70: 2823-2836
        • Mishra S
        • Sadagopan N
        • Dunkerly-Eyring B
        • et al.
        Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice.
        J Clin Invest. 2021; 131
        • Forfia PR
        • Lee M
        • Tunin RS
        • et al.
        Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
        J Am Coll Cardiol. 2007; 49: 1079-1088
        • Nakatsuji H
        • Maeda N
        • Hibuse T
        • et al.
        Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells.
        Biochem Biophys Res Commun. 2010; 392: 100-105
        • Maack T
        • Suzuki M
        • Almeida FA
        • et al.
        Physiological role of silent receptors of atrial natriuretic factor.
        Science. 1987; 238: 675-678
        • Anand-Srivastava MB
        • Sairam MR
        • Cantin M.
        Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system.
        J Biol Chem. 1990; 265: 8566-8572
        • Nishizawa N
        • Nakamura G
        • Noguchi Y
        • et al.
        A potent and selective natriuretic peptide receptor-3 blocker 11-mer peptide created by hybridization of musclin and atrial natriuretic peptide.
        Bioorg Med Chem Lett. 2017; 27: 3542-3545
        • Hudkins KL
        • Pichaiwong W
        • Wietecha T
        • et al.
        BTBR Ob/Ob mutant mice model progressive diabetic nephropathy.
        J Am Soc Nephrol. 2010; 21: 1533-1542
        • Soler MJ
        • Riera M
        • Batlle D.
        New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy.
        Exp Diabetes Res. 2012; 2012616313
        • Pichaiwong W
        • Hudkins KL
        • Wietecha T
        • et al.
        Reversibility of structural and functional damage in a model of advanced diabetic nephropathy.
        J Am Soc Nephrol. 2013; 24: 1088-1102
        • Li Y
        • Sarkar O
        • Brochu M
        • et al.
        Natriuretic peptide receptor-C attenuates hypertension in spontaneously hypertensive rats: role of nitroxidative stress and Gi proteins.
        Hypertension. 2014; 63: 846-855
        • Wang L
        • Tang Y
        • Buckley AF
        • et al.
        Blockade of the natriuretic peptide clearance receptor attenuates proteinuria in a mouse model of focal segmental glomerulosclerosis.
        Physiol Rep. 2021; 9: e15095
        • Westerterp KR.
        Control of energy expenditure in humans.
        Eur J Clin Nutr. 2017; 71: 340-344
        • Tschop MH
        • Speakman JR
        • Arch JR
        • et al.
        A guide to analysis of mouse energy metabolism.
        Nat Methods. 2011; 9: 57-63
        • Wu HT
        • Chang CK
        • Cheng KC
        • et al.
        Increase of plasma insulin by racecadotril, an inhibitor of enkephalinase, in Wistar rats.
        Horm Metab Res. 2010; 42: 261-267
        • Undank S
        • Kaiser J
        • Sikimic J
        • et al.
        Atrial natriuretic peptide affects stimulus-secretion coupling of pancreatic beta-cells.
        Diabetes. 2017; 66: 2840-2848
        • Uehlinger DE
        • Weidmann P
        • Gnadinger MP
        • et al.
        Increase in circulating insulin induced by atrial natriuretic peptide in normal humans.
        J Cardiovasc Pharmacol. 1986; 8: 1122-1129
        • Olefsky JM
        • Glass CK.
        Macrophages, inflammation, and insulin resistance.
        Annu Rev Physiol. 2010; 72: 219-246
        • Hirsch S
        • Austyn JM
        • Gordon S.
        Expression of the macrophage-specific antigen F4/80 during differentiation of mouse bone marrow cells in culture.
        J Exp Med. 1981; 154: 713-725
        • McKnight AJ
        • Macfarlane AJ
        • Dri P
        • et al.
        Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein-linked transmembrane 7 hormone receptor family.
        J Biol Chem. 1996; 271: 486-489
        • Sengenes C
        • Bouloumie A
        • Hauner H
        • et al.
        Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes.
        J Biol Chem. 2003; 278: 48617-48626
        • Vargas-Castillo A
        • Fuentes-Romero R
        • Rodriguez-Lopez LA
        • et al.
        Understanding the biology of thermogenic fat: is browning a new approach to the treatment of obesity?.
        Arch Med Res. 2017; 48: 401-413
        • Lynch MR
        • Tran MT
        • Parikh SM.
        PGC1alpha in the kidney.
        Am J Physiol Renal Physiol. 2018; 314: F1-F8
        • Wang S
        • Yang X.
        Inter-organ regulation of adipose tissue browning.
        Cell Mol Life Sci. 2017; 74: 1765-1776
        • Vitali A
        • Murano I
        • Zingaretti MC
        • et al.
        The adipose organ of obesity-prone C57BL/6J mice is composed of mixed white and brown adipocytes.
        J Lipid Res. 2012; 53: 619-629
        • Wu J
        • Bostrom P
        • Sparks LM
        • et al.
        Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human.
        Cell. 2012; 150: 366-376
        • Perez-Ternero C
        • Aubdool AA
        • Makwana R
        • et al.
        C-type natriuretic peptide is a pivotal regulator of metabolic homeostasis.
        Proc Natl Acad Sci U S A. 2022; 119e2116470119
        • Rose RA
        • Giles WR.
        Natriuretic peptide C receptor signalling in the heart and vasculature.
        J Physiol. 2008; 586: 353-366
        • Vila G
        • Grimm G
        • Resl M
        • et al.
        B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men.
        Diabetes. 2012; 61: 2592-2596
        • Virtue S
        • Even P
        • Vidal-Puig A.
        Below thermoneutrality, changes in activity do not drive changes in total daily energy expenditure between groups of mice.
        Cell Metab. 2012; 16: 665-671
        • Sabbatini ME.
        Natriuretic peptides as regulatory mediators of secretory activity in the digestive system.
        Regul Pept. 2009; 154: 5-15
        • Biro M
        • Munoz MA
        • Weninger W.
        Targeting Rho-GTPases in immune cell migration and inflammation.
        Br J Pharmacol. 2014; 171: 5491-5506
        • Yoshimura A
        • Wakabayashi Y
        • Mori T.
        Cellular and molecular basis for the regulation of inflammation by TGF-beta.
        J Biochem. 2010; 147: 781-792
        • Rossol M
        • Pierer M
        • Raulien N
        • et al.
        Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors.
        Nat Commun. 2012; 3: 1329
        • Sipka T
        • Peroceschi R
        • Hassan-Abdi R
        • et al.
        Damage-induced calcium signaling and reactive oxygen species mediate macrophage activation in zebrafish.
        Front Immunol. 2021; 12636585
        • Flowers JB
        • Oler AT
        • Nadler ST
        • et al.
        Abdominal obesity in BTBR male mice is associated with peripheral but not hepatic insulin resistance.
        Am J Physiol Endocrinol Metab. 2007; 292: E936-E945
        • Meirhaeghe A
        • Sandhu MS
        • McCarthy MI
        • et al.
        Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations.
        Hum Mol Genet. 2007; 16: 1343-1350
        • Choquet H
        • Cavalcanti-Proenca C
        • Lecoeur C
        • et al.
        The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects.
        Hum Mol Genet. 2009; 18: 2495-2501
        • McMurray JJ
        • Packer M
        • Desai AS
        • et al.
        Angiotensin-neprilysin inhibition versus enalapril in heart failure.
        N Engl J Med. 2014; 371: 993-1004
        • Staffel J
        • Valletta D
        • Federlein A
        • et al.
        Natriuretic peptide receptor guanylyl cyclase-A in podocytes is renoprotective but dispensable for physiologic renal function.
        J Am Soc Nephrol. 2017; 28: 260-277
        • Kato Y
        • Mori K
        • Kasahara M
        • et al.
        Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition.
        Sci Rep. 2017; 7: 46624
        • Haynes R
        • Judge PK
        • Staplin N
        • et al.
        Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease.
        Circulation. 2018; 138: 1505-1514
        • Scheele W
        • Diamond S
        • Gale J
        • et al.
        Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy.
        J Am Soc Nephrol. 2016; 27: 3459-3468